0001209191-18-047864.txt : 20180821 0001209191-18-047864.hdr.sgml : 20180821 20180821194627 ACCESSION NUMBER: 0001209191-18-047864 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180821 FILED AS OF DATE: 20180821 DATE AS OF CHANGE: 20180821 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zhou Quan CENTRAL INDEX KEY: 0001747536 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38613 FILM NUMBER: 181031234 MAIL ADDRESS: STREET 1: C/O BIONANO GENOMICS, INC. STREET 2: 9640 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BioNano Genomics, Inc CENTRAL INDEX KEY: 0001411690 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 9640 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 888-7600 MAIL ADDRESS: STREET 1: 9640 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: BioNanomatrix Inc DATE OF NAME CHANGE: 20070906 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-08-21 0 0001411690 BioNano Genomics, Inc BNGO 0001747536 Zhou Quan C/O BIONANO GENOMICS, INC. 9640 TOWNE CENTRE DRIVE, SUITE 100 SAN DIEGO CA 92121 1 0 1 0 Series C Convertible Preferred Stock 0.00 Common Stock 8545184 I By entities affiliated with LC Fund VI, L.P. Series D Convertible Preferred Stock 0.00 Common Stock 6443565 I By entities affiliated with LC Fund VI, L.P. Series D-1 Convertible Preferred Stock 0.00 Common Stock 27305708 I By entities affiliated with LC Fund VI, L.P. Series D Convertible Preferred Stock Warrants (Right to Buy) 0.41 2016-03-04 2026-03-04 Series D Convertible Preferred Stock 11263624 I By entities affiliated with LC Fund VI, L.P. The convertible preferred stock is convertible at any time at the holder's election and automatically converts upon the consummation of a qualified public offering of the registrant. There is no expiration date for any series of preferred stock. The shares are held as follows: 8,203,376 shares held by LC Fund VI, L.P. ("LC Fund") and 341,808 shares held by LC Parallel Fund VI, L.P. ("Parallel Fund") LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein. The shares are held as follows: 6,143,224 shares held by LC Fund and 300,341 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein. The shares are held as follows: 3,924,722 shares held by LC Fund, 241,948 shares held by Parallel Fund and 23,139,038 shares held by LC Healthcare Fund I, L.P. ("Healthcare Fund"). LC Fund, Parallel Fund and Healthcare Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein. The warrants are held as follows: warrant to purchase 10,738,615 shares held by LC Fund and warrant to purchase 525,009 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein. /s/ Heather Adams, Attorney-in-Fact 2018-08-21 EX-24.3_806512 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all, by these presents, that the undersigned hereby constitutes and appoints each of R. Erik Holmlin, Michael Ward and Heather Adams, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of BioNano Genomics, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of July, 2018. /s/ Quan Zhou